DOI:

Comparison of new EuroSCORE II with logistic EuroSCORE and STS score in predicting 30-day and one-year mortality in patients undergoing TAVI

Hashmi I., Rajagopal R., Gardezi S., Wojciuk J., More R., Rogers S., Tassiker J., Tang A., Sogliani F., Roberts D.

Risk assesment in TAVI including valve-in-valve

Comparison of new EuroSCORE II with logistic EuroSCORE and STS score in predicting 30-day and one-year mortality in patients undergoing TAVI

Aims: The validity of the logistic EuroSCORE (LES) and STS score for risk stratification in patients undergoing TAVI is questionable. The purpose of this study was to compare the newly created EuroSCORE II (ES II) with the LES and STS score in patients undergoing TAVI by Medtronic CoreValve or Edwards SAPIEN after formal turn-down for surgical AVR.

Methods and results: Eighty-two consecutive patients in a single institution underwent TAVI via the transfemoral, trans-subclavian, transapical and direct aortic approaches. Estimated LES, ES II and STS score were calculated retrospectively. The 30-day mortality was 7.3% (6/82) and the one-year mortality was 23.2% (19/82). The mean LES of patients who did not survive at 30 days was 33% and among survivors it was 23.5% (p=0.8; RR 1.4, 95% CI 0.44-4.46). The ES II at 30 days was 20.1% in non-survivors and 10.3% in survivors (p=0.62, RR 1.96, 95% CI 0.61 - 6.32). The STS score was 9.1% and 7.6% (p=0.87; RR 1.2, 95% CI 0.5-2.89) in non-survivors and survivors respectively. At one-year, the mean LES in non-survivors was 28.2% and 22.9% in survivors (p=0.84; RR 1.23, 95% CI 0.51-3.0). ES II was 13.9% and 10.2% (p=0.79; RR 1.36, 95% CI 0.5-3.71). The STS score was 8% and 7.6% (p=0.95; RR 1.05, 95% CI 0.52-2.14). Overall there was no difference in the relative risk between the non-survivors and survivors based on any of the three risk scores. We then classified the patients into low, intermediate and high risk groups (LES <10, 10-20, >20%, ES II <5, 5-10, >10% and STS <5, 5-10, >10% respectively) and analysed the 30-day and one-year mortality. Patients in the high ES II risk group (>10%) had higher mortality compared with both low-risk and intermediate-risk groups at 30 days and one year following TAVI, although this failed to reach statistical significance. In contrast the LES and STS score did not show any consistent trends among the three risk groups.

Conclusions: ES II was no better than LES or STS score in predicting 30-day or one-year mortality in patients undergoing TAVI after formal surgical turn-down. ES II may predict mortality better in the highest risk group. This study highlights the deficiencies of all three surgical risk scores in predicting mortality in patients undergoing TAVI and thus the need to develop a dedicated TAVI risk score system.

Volume 8 Supplement Q
Sep 30, 2012
Volume 8 Supplement Q
View full issue


Key metrics

Suggested by Cory

CLINICAL RESEARCH

10.4244/EIJ-D-17-00421 Jan 19, 2018
TAVI risk scoring using established versus new scoring systems: role of the new STS/ACC model
Arsalan M et al
free

10.4244/EIJV13I13A241 Jan 19, 2018
The business of risk
Lennon R and Holmes D
free

10.4244/EIJV11SWA6 Sep 17, 2015
Measuring risk in valvular interventions: from low risk to futility
Kappetein A
free
Trending articles
166.7

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
92.45

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
73.05

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
60.55

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
58.3

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
26

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved